English

BIOANALYTICAL SYSTEMS INC

EDGAR

BASI Quarterly report (10-Q) · filed 2026-05-11

Annual consolidated revenue for 2025: about USD 513M, using the latest reported figures. The previous period, 2024, was about USD 490.7M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

118 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 117652000 USD Source

Operating margin

-16.41%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -19309000 USD Source
Revenue: 117652000 USD Source

Operating cash flow

-1.07 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -6503000 USD Source
Operating Cash Flow: -5433000 USD Source

Cash and cash equivalents: 15.2 million USD 2026-03-31 Source
Exact value

15180000 USD
Long-term debt including current maturities: 410 million USD 2026-03-31 Source
Exact value

410422000 USD
Shares outstanding: 34.9 million shares 2026-03-31 Source
Exact value

34888147 shares

Reported share-count change

1.57% · 540 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

34348540 shares · 2025-03-31· Source
34888147 shares · 2026-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-05-11.

Financial data available through: 2025-09-30.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2025-09-30
Operating income: 8 of 11 periods available· newest 2025-09-30
Net income: 8 of 11 periods available· newest 2025-09-30
Operating cash flow: 8 of 11 periods available· newest 2025-09-30
capital expenditure: No compatible figures in this window
Total assets: 8 of 11 periods available· newest 2025-09-30
Total liabilities: 8 of 11 periods available· newest 2025-09-30
Current assets: 8 of 11 periods available· newest 2025-09-30
Current liabilities: 8 of 11 periods available· newest 2025-09-30
Cash and cash equivalents: 8 of 11 periods available· newest 2025-09-30
Long-term debt including current maturities: 8 of 11 periods available· newest 2025-09-30
Shares outstanding: 8 of 11 periods available· newest 2025-09-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+4.5%

Prior period

USD 490.74 million

2023-10-01 – 2024-09-30
Current period

USD 513.02 million

2024-10-01 – 2025-09-30

Exact inputs and evidence

513024000 − 490739000 = 22285000 USD

490739000 USD · 2023-10-01 – 2024-09-30
Inspect prior input Prior source
513024000 USD · 2024-10-01 – 2025-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · BIOANALYTICAL SYSTEMS INC · 2025-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Year-over-year change in Revenue: 22285000 USD Concept: fundies:Revenue Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 513024000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1514421 Filing: 000162828025055483 Input fundies:Revenue: 490739000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1515396 Filing: 000162828025055483
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 39.82 million

Prior period

−USD 108.45 million

2023-10-01 – 2024-09-30
Current period

−USD 68.63 million

2024-10-01 – 2025-09-30

Exact inputs and evidence

-68625000 − -108445000 = 39820000 USD

-108445000 USD · 2023-10-01 – 2024-09-30
Inspect prior input Prior source
-68625000 USD · 2024-10-01 – 2025-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BIOANALYTICAL SYSTEMS INC · 2025-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Year-over-year change in Net income: 39820000 USD Concept: fundies:NetIncome Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -68625000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#2099835 Filing: 000162828025055483 Input fundies:NetIncome: -108445000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#2100459 Filing: 000162828025055483
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 3.65 million

Prior period

−USD 6.81 million

2023-10-01 – 2024-09-30
Current period

−USD 10.46 million

2024-10-01 – 2025-09-30

Exact inputs and evidence

-10455000 − -6805000 = -3650000 USD

-6805000 USD · 2023-10-01 – 2024-09-30
Inspect prior input Prior source
-10455000 USD · 2024-10-01 – 2025-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BIOANALYTICAL SYSTEMS INC · 2025-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Year-over-year change in Operating cash flow: -3650000 USD Concept: fundies:OperatingCashFlow Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -10455000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1232243 Filing: 000162828025055483 Input fundies:OperatingCashFlow: -6805000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1232896 Filing: 000162828025055483
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2024-10-01 – 2025-09-30

Revenue USD 513.02 million 100% of revenue
Operating costs Derived USD 543.93 million 106% of revenue
Operating income −USD 30.9 million −6% of revenue
Tax, interest and other Derived USD 37.72 million 7.4% of revenue
Net income −USD 68.63 million −13% of revenue

Cash

Operating cash flow −USD 10.46 million −2% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Net income was higher than operating income, so the split is not drawn.
2016 Operating loss: operating costs were 115% of revenue.
2017 95%
2018 Net loss: net income was −0.7% of revenue.
2022 Operating loss: operating costs were 148% of revenue.
2023 Operating loss: operating costs were 114% of revenue.
2024 Operating loss: operating costs were 118% of revenue.
2025 Operating loss: operating costs were 106% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2014-10-01 – 2015-09-30	22698000	21789000 Derived	909000	-190000 Derived	1099000	Unavailable	Source 2014-10-01 – 2015-09-30: 22698000 USD Inspect Revenue Open source 2014-10-01 – 2015-09-30: 909000 USD Inspect Operating Income Open source 2014-10-01 – 2015-09-30: 1099000 USD Inspect Net Income Open source 2014-10-01 – 2015-09-30: 2104000 USD Inspect Operating Cash Flow Open source
2016 2015-10-01 – 2016-09-30	20441000	23481000 Derived	-3040000	190000 Derived	-3230000	Unavailable	Source 2015-10-01 – 2016-09-30: 20441000 USD Inspect Revenue Open source 2015-10-01 – 2016-09-30: -3040000 USD Inspect Operating Income Open source 2015-10-01 – 2016-09-30: -3230000 USD Inspect Net Income Open source 2015-10-01 – 2016-09-30: 1060000 USD Inspect Operating Cash Flow Open source
2017 2016-10-01 – 2017-09-30	24242000	22964000 Derived	1278000	394000 Derived	884000	Unavailable	Source 2016-10-01 – 2017-09-30: 24242000 USD Inspect Revenue Open source 2016-10-01 – 2017-09-30: 1278000 USD Inspect Operating Income Open source 2016-10-01 – 2017-09-30: 884000 USD Inspect Net Income Open source 2016-10-01 – 2017-09-30: 1236000 USD Inspect Operating Cash Flow Open source
2018 2017-10-01 – 2018-09-30	26346000	26332000 Derived	14000	208000 Derived	-194000	Unavailable	Source 2017-10-01 – 2018-09-30: 26346000 USD Inspect Revenue Open source 2017-10-01 – 2018-09-30: 14000 USD Inspect Operating Income Open source 2017-10-01 – 2018-09-30: -194000 USD Inspect Net Income Open source 2017-10-01 – 2018-09-30: 3487000 USD Inspect Operating Cash Flow Open source
2022 2021-10-01 – 2022-09-30	547656000	811108000 Derived	-263452000	73566000 Derived	-337018000	Unavailable	Source 2021-10-01 – 2022-09-30: 547656000 USD Inspect Revenue Open source 2021-10-01 – 2022-09-30: -263452000 USD Inspect Operating Income Open source 2021-10-01 – 2022-09-30: -337018000 USD Inspect Net Income Open source 2021-10-01 – 2022-09-30: -5217000 USD Inspect Operating Cash Flow Open source
2023 2022-10-01 – 2023-09-30	572425000	653885000 Derived	-81460000	23680000 Derived	-105140000	Unavailable	Source 2022-10-01 – 2023-09-30: 572425000 USD Inspect Revenue Open source 2022-10-01 – 2023-09-30: -81460000 USD Inspect Operating Income Open source 2022-10-01 – 2023-09-30: -105140000 USD Inspect Net Income Open source 2022-10-01 – 2023-09-30: 27883000 USD Inspect Operating Cash Flow Open source
2024 2023-10-01 – 2024-09-30	490739000	577145000 Derived	-86406000	22039000 Derived	-108445000	Unavailable	Source 2023-10-01 – 2024-09-30: 490739000 USD Inspect Revenue Open source 2023-10-01 – 2024-09-30: -86406000 USD Inspect Operating Income Open source 2023-10-01 – 2024-09-30: -108445000 USD Inspect Net Income Open source 2023-10-01 – 2024-09-30: -6805000 USD Inspect Operating Cash Flow Open source
2025 2024-10-01 – 2025-09-30	513024000	543926000 Derived	-30902000	37723000 Derived	-68625000	Unavailable	Source 2024-10-01 – 2025-09-30: 513024000 USD Inspect Revenue Open source 2024-10-01 – 2025-09-30: -30902000 USD Inspect Operating Income Open source 2024-10-01 – 2025-09-30: -68625000 USD Inspect Net Income Open source 2024-10-01 – 2025-09-30: -10455000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 513M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Revenue	22698000	Revenue: 22698000 Open source
20162016-09-30	Revenue	20441000	Revenue: 20441000 Open source
20172017-09-30	Revenue	24242000	Revenue: 24242000 Open source
20182018-09-30	Revenue	26346000	Revenue: 26346000 Open source
20222022-09-30	Revenue	547656000	Revenue: 547656000 Open source
20232023-09-30	Revenue	572425000	Revenue: 572425000 Open source
20242024-09-30	Revenue	490739000	Revenue: 490739000 Open source
20252025-09-30	Revenue	513024000	Revenue: 513024000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

4.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Year over year	No prior comparable period	Revenue: 22698000 Open source
20162016-09-30	Year over year	-9.9%	Revenue: 20441000 Open source Revenue: 22698000 Open source
20172017-09-30	Year over year	18.6%	Revenue: 24242000 Open source Revenue: 20441000 Open source
20182018-09-30	Year over year	8.7%	Revenue: 26346000 Open source Revenue: 24242000 Open source
20222022-09-30	Year over year	No prior comparable period	Revenue: 547656000 Open source
20232023-09-30	Year over year	4.5%	Revenue: 572425000 Open source Revenue: 547656000 Open source
20242024-09-30	Year over year	-14.3%	Revenue: 490739000 Open source Revenue: 572425000 Open source
20252025-09-30	Year over year	4.5%	Revenue: 513024000 Open source Revenue: 490739000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -6% 2025

Net margin -13.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Operating margin	4%	Operating Income: 909000 Open source Revenue: 22698000 Open source
20162016-09-30	Operating margin	-14.9%	Operating Income: -3040000 Open source Revenue: 20441000 Open source
20172017-09-30	Operating margin	5.3%	Operating Income: 1278000 Open source Revenue: 24242000 Open source
20182018-09-30	Operating margin	0.1%	Operating Income: 14000 Open source Revenue: 26346000 Open source
20222022-09-30	Operating margin	-48.1%	Operating Income: -263452000 Open source Revenue: 547656000 Open source
20232023-09-30	Operating margin	-14.2%	Operating Income: -81460000 Open source Revenue: 572425000 Open source
20242024-09-30	Operating margin	-17.6%	Operating Income: -86406000 Open source Revenue: 490739000 Open source
20252025-09-30	Operating margin	-6%	Operating Income: -30902000 Open source Revenue: 513024000 Open source
20152015-09-30	Net margin	4.8%	Net Income: 1099000 Open source Revenue: 22698000 Open source
20162016-09-30	Net margin	-15.8%	Net Income: -3230000 Open source Revenue: 20441000 Open source
20172017-09-30	Net margin	3.6%	Net Income: 884000 Open source Revenue: 24242000 Open source
20182018-09-30	Net margin	-0.7%	Net Income: -194000 Open source Revenue: 26346000 Open source
20222022-09-30	Net margin	-61.5%	Net Income: -337018000 Open source Revenue: 547656000 Open source
20232023-09-30	Net margin	-18.4%	Net Income: -105140000 Open source Revenue: 572425000 Open source
20242024-09-30	Net margin	-22.1%	Net Income: -108445000 Open source Revenue: 490739000 Open source
20252025-09-30	Net margin	-13.4%	Net Income: -68625000 Open source Revenue: 513024000 Open source
20152015-09-30	Free cash flow margin	Not reported	Revenue: 22698000 Open source Operating Cash Flow: 2104000 Open source
20162016-09-30	Free cash flow margin	Not reported	Revenue: 20441000 Open source Operating Cash Flow: 1060000 Open source
20172017-09-30	Free cash flow margin	Not reported	Revenue: 24242000 Open source Operating Cash Flow: 1236000 Open source
20182018-09-30	Free cash flow margin	Not reported	Revenue: 26346000 Open source Operating Cash Flow: 3487000 Open source
20222022-09-30	Free cash flow margin	Not reported	Revenue: 547656000 Open source Operating Cash Flow: -5217000 Open source
20232023-09-30	Free cash flow margin	Not reported	Revenue: 572425000 Open source Operating Cash Flow: 27883000 Open source
20242024-09-30	Free cash flow margin	Not reported	Revenue: 490739000 Open source Operating Cash Flow: -6805000 Open source
20252025-09-30	Free cash flow margin	Not reported	Revenue: 513024000 Open source Operating Cash Flow: -10455000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -10.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Operating cash flow	2104000	Operating Cash Flow: 2104000 Open source
20162016-09-30	Operating cash flow	1060000	Operating Cash Flow: 1060000 Open source
20172017-09-30	Operating cash flow	1236000	Operating Cash Flow: 1236000 Open source
20182018-09-30	Operating cash flow	3487000	Operating Cash Flow: 3487000 Open source
20222022-09-30	Operating cash flow	-5217000	Operating Cash Flow: -5217000 Open source
20232023-09-30	Operating cash flow	27883000	Operating Cash Flow: 27883000 Open source
20242024-09-30	Operating cash flow	-6805000	Operating Cash Flow: -6805000 Open source
20252025-09-30	Operating cash flow	-10455000	Operating Cash Flow: -10455000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Free cash flow	Unavailable	Operating Cash Flow: 2104000 Open source
20162016-09-30	Free cash flow	Unavailable	Operating Cash Flow: 1060000 Open source
20172017-09-30	Free cash flow	Unavailable	Operating Cash Flow: 1236000 Open source
20182018-09-30	Free cash flow	Unavailable	Operating Cash Flow: 3487000 Open source
20222022-09-30	Free cash flow	Unavailable	Operating Cash Flow: -5217000 Open source
20232023-09-30	Free cash flow	Unavailable	Operating Cash Flow: 27883000 Open source
20242024-09-30	Free cash flow	Unavailable	Operating Cash Flow: -6805000 Open source
20252025-09-30	Free cash flow	Unavailable	Operating Cash Flow: -10455000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

82.4% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Liabilities / assets	55%	Total Liabilities: 13087000 Open source Total Assets: 23815000 Open source
20162016-09-30	Liabilities / assets	64.7%	Total Liabilities: 13671000 Open source Total Assets: 21129000 Open source
20172017-09-30	Liabilities / assets	58.5%	Total Liabilities: 11950000 Open source Total Assets: 20417000 Open source
20182018-09-30	Liabilities / assets	65.2%	Total Liabilities: 20384000 Open source Total Assets: 31268000 Open source
20222022-09-30	Liabilities / assets	62.6%	Total Liabilities: 603134000 Open source Total Assets: 962900000 Open source
20232023-09-30	Liabilities / assets	68.7%	Total Liabilities: 588040000 Open source Total Assets: 856530000 Open source
20242024-09-30	Liabilities / assets	78.2%	Total Liabilities: 610857000 Open source Total Assets: 781361000 Open source
20252025-09-30	Liabilities / assets	82.4%	Total Liabilities: 635086000 Open source Total Assets: 771114000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.35× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Current assets / current liabilities	0.72×	Current Assets: 6676000 Open source Current Liabilities: 9303000 Open source
20162016-09-30	Current assets / current liabilities	0.36×	Current Assets: 4877000 Open source Current Liabilities: 13473000 Open source
20172017-09-30	Current assets / current liabilities	0.69×	Current Assets: 5306000 Open source Current Liabilities: 7723000 Open source
20182018-09-30	Current assets / current liabilities	0.68×	Current Assets: 8061000 Open source Current Liabilities: 11801000 Open source
20222022-09-30	Current assets / current liabilities	1.42×	Current Assets: 232977000 Open source Current Liabilities: 164099000 Open source
20232023-09-30	Current assets / current liabilities	1.62×	Current Assets: 213803000 Open source Current Liabilities: 132194000 Open source
20242024-09-30	Current assets / current liabilities	1.37×	Current Assets: 163413000 Open source Current Liabilities: 119042000 Open source
20252025-09-30	Current assets / current liabilities	0.35×	Current Assets: 194591000 Open source Current Liabilities: 556784000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2014-10-01 – 2015-09-30	USD 1.1 million Exact value Exact value: 1099000 USD 2014-10-01 – 2015-09-30: 1099000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2015-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: 1099000 USD Concept: fundies:NetIncome Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:NetIncome: 1099000 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420416141558/basi-20160930.xml#105685 Filing: 000114420416141558 The citation records this snapshot. The page link may show a newer release later.	USD 2.1 million Exact value Exact value: 2104000 USD 2014-10-01 – 2015-09-30: 2104000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2015-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: 2104000 USD Concept: fundies:OperatingCashFlow Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2104000 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420416141558/basi-20160930.xml#113109 Filing: 000114420416141558 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2015-10-01 – 2016-09-30	−USD 3.23 million Exact value Exact value: -3230000 USD 2015-10-01 – 2016-09-30: -3230000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2016-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: -3230000 USD Concept: fundies:NetIncome Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:NetIncome: -3230000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420417065076/basi-20170930.xml#85371 Filing: 000114420417065076 The citation records this snapshot. The page link may show a newer release later.	USD 1.06 million Exact value Exact value: 1060000 USD 2015-10-01 – 2016-09-30: 1060000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2016-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: 1060000 USD Concept: fundies:OperatingCashFlow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1060000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420417065076/basi-20170930.xml#1372623 Filing: 000114420417065076 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2016-10-01 – 2017-09-30	USD 884,000 Exact value Exact value: 884000 USD 2016-10-01 – 2017-09-30: 884000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2017-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: 884000 USD Concept: fundies:NetIncome Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:NetIncome: 884000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420418066005/basi-20180930.xml#85428 Filing: 000114420418066005 The citation records this snapshot. The page link may show a newer release later.	USD 1.24 million Exact value Exact value: 1236000 USD 2016-10-01 – 2017-09-30: 1236000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2017-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: 1236000 USD Concept: fundies:OperatingCashFlow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1236000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420418066005/basi-20180930.xml#268771 Filing: 000114420418066005 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2017-10-01 – 2018-09-30	−USD 194,000 Exact value Exact value: -194000 USD 2017-10-01 – 2018-09-30: -194000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2018-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: -194000 USD Concept: fundies:NetIncome Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:NetIncome: -194000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420418066005/basi-20180930.xml#85288 Filing: 000114420418066005 The citation records this snapshot. The page link may show a newer release later.	USD 3.49 million Exact value Exact value: 3487000 USD 2017-10-01 – 2018-09-30: 3487000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2018-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: 3487000 USD Concept: fundies:OperatingCashFlow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3487000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000114420418066005/basi-20180930.xml#268573 Filing: 000114420418066005 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2021-10-01 – 2022-09-30	−USD 337.02 million Exact value Exact value: -337018000 USD 2021-10-01 – 2022-09-30: -337018000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2022-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: -337018000 USD Concept: fundies:NetIncome Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:NetIncome: -337018000 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828023041266/notv-20230930.htm#1920074 Filing: 000162828023041266 The citation records this snapshot. The page link may show a newer release later.	−USD 5.22 million Exact value Exact value: -5217000 USD 2021-10-01 – 2022-09-30: -5217000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2022-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: -5217000 USD Concept: fundies:OperatingCashFlow Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5217000 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828023041266/notv-20230930.htm#1104715 Filing: 000162828023041266 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2022-10-01 – 2023-09-30	−USD 105.14 million Exact value Exact value: -105140000 USD 2022-10-01 – 2023-09-30: -105140000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2023-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: -105140000 USD Concept: fundies:NetIncome Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:NetIncome: -105140000 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#2101085 Filing: 000162828025055483 The citation records this snapshot. The page link may show a newer release later.	USD 27.88 million Exact value Exact value: 27883000 USD 2022-10-01 – 2023-09-30: 27883000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2023-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: 27883000 USD Concept: fundies:OperatingCashFlow Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 27883000 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1233548 Filing: 000162828025055483 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2023-10-01 – 2024-09-30	−USD 108.45 million Exact value Exact value: -108445000 USD 2023-10-01 – 2024-09-30: -108445000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2024-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: -108445000 USD Concept: fundies:NetIncome Period: 2023-10-01 to 2024-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2024-09-30&surface=latest&period_type=duration&start=2023-10-01&unit=USD&dimensions= Input fundies:NetIncome: -108445000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#2100459 Filing: 000162828025055483 The citation records this snapshot. The page link may show a newer release later.	−USD 6.81 million Exact value Exact value: -6805000 USD 2023-10-01 – 2024-09-30: -6805000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2024-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: -6805000 USD Concept: fundies:OperatingCashFlow Period: 2023-10-01 to 2024-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2024-09-30&surface=latest&period_type=duration&start=2023-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6805000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1232896 Filing: 000162828025055483 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2024-10-01 – 2025-09-30	−USD 68.63 million Exact value Exact value: -68625000 USD 2024-10-01 – 2025-09-30: -68625000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOANALYTICAL SYSTEMS INC · 2025-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Net Income: -68625000 USD Concept: fundies:NetIncome Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3ANetIncome&period=2025-09-30&surface=latest&period_type=duration&start=2024-10-01&unit=USD&dimensions= Input fundies:NetIncome: -68625000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#2099835 Filing: 000162828025055483 The citation records this snapshot. The page link may show a newer release later.	−USD 10.46 million Exact value Exact value: -10455000 USD 2024-10-01 – 2025-09-30: -10455000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOANALYTICAL SYSTEMS INC · 2025-09-30 BIOANALYTICAL SYSTEMS INC (edgar:720154) Operating Cash Flow: -10455000 USD Concept: fundies:OperatingCashFlow Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/720154/explain?concept=fundies%3AOperatingCashFlow&period=2025-09-30&surface=latest&period_type=duration&start=2024-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10455000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm#1232243 Filing: 000162828025055483 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

149 filings · 8,311 latest values · 8,311 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000720154, 720154, BASI, BASi, NOTV, basi, edgar:720154

Also known as BIOANALYTICAL SYSTEMS INC, INOTIV, INC., INOTIV, INC., Inotiv, Inc.

BIOANALYTICAL SYSTEMS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2024-10-01 – 2025-09-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation